TZ Ref No.: TZ-26-1417361
REACT-CK1 - Revolutionizing AML Therapy - A First-in-Class CK1 Inhibitor for Relapsed Refractory Patients
Doc ref no.
1013•••
Sector
Healthcare and Medicine
Contract Date
14 Jul 2026
Contract Value
EUR ••••••
Contract Intelligence
AI opportunity notes and scope analysis for this contract award
Opportunity Notes
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Official Award Result
Status: Contract Awarded
Award Date: 14 Jul 2026
Awarded Contractor / Winner
CASI•••
Awarded Contract Value:
EUR 485,034.38
Execution Period:
01 Aug 2026 → 31 Jul 2028
(730 days)
Contract Description
Relapsed or refractory acute myeloid leukaemia (AML) in patients after the state of the art treatment with venetoclax plus azacitidine remains a critical unmet medical need, with median survival often measured in weeks and no approved mutation-agnostic therapeutic options. The...